So while the announcement about Part D premium hikes might have come from President Donald Trump’s CMS, his administration is merely the messenger. If seniors want to know who is responsible for this looming shift in their financial circumstances, they need only look to Biden.
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank.
According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase substantially next year. This is just the latest evidence that the IRA’s Medicare reforms, touted by Democrats as a gift to seniors, are in fact anything but.
How, exactly, did the IRA go so terribly wrong for Medicare patients? There is no single cause, but several provisions aimed at reducing seniors’ drug costs are certainly to blame.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Sally C. Pipes
So while the announcement about Part D premium hikes might have come from President Donald Trump’s CMS, his administration is merely the messenger. If seniors want to know who is responsible for this looming shift in their financial circumstances, they need only look to Biden.
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank.
According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase substantially next year. This is just the latest evidence that the IRA’s Medicare reforms, touted by Democrats as a gift to seniors, are in fact anything but.
How, exactly, did the IRA go so terribly wrong for Medicare patients? There is no single cause, but several provisions aimed at reducing seniors’ drug costs are certainly to blame.
Read the op-ed here.
Nothing contained in this blog is to be construed as necessarily reflecting the views of the Pacific Research Institute or as an attempt to thwart or aid the passage of any legislation.